Nektar Therapeutics (NKTR) Gains from Investment Securities (2010 - 2024)

Nektar Therapeutics' Gains from Investment Securities history runs 15 years deep, the most recent figure standing at -$7.6 million for Q4 2024.

• In Q4 2024, Gains from Investment Securities fell 93.0% year-over-year to -$7.6 million; the TTM figure through Dec 2024 stood at $76000.0 (up 105.85% YoY), while the FY2025 annual figure was -$195000.0, down 356.58% from the prior year.
• Gains from Investment Securities was -$7.6 million for Q4 2024 at Nektar Therapeutics, down from $2.1 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $5.7 million in Q4 2021 to a low of -$7.6 million in Q4 2024.
• Historically, Gains from Investment Securities has averaged -$38055.6 across 5 years, with a median of $1.1 million in 2020.
• The sharpest annual moves came in 2021 and 2023: Gains from Investment Securities jumped 456.15% in 2021, then tumbled 6363.53% in 2023.
• A 5-year view of Gains from Investment Securities shows it stood at -$1.6 million in 2020, then surged by 456.15% to $5.7 million in 2021, then plunged by 101.5% to -$85000.0 in 2022, then plunged by 4554.12% to -$4.0 million in 2023, then plunged by 93.0% to -$7.6 million in 2024.
• The last three Gains from Investment Securities figures came in at -$7.6 million (Q4 2024), $2.1 million (Q3 2024), and $2.6 million (Q2 2024), per Business Quant data.